Rezolute's Phase 3 sunRIZE Study Misses Primary Endpoints for Congenital HI; Tumor HI EAP Shows Strong Positive Results

summarizeSummary

Rezolute's Phase 3 sunRIZE study for congenital hyperinsulinism missed its primary endpoints, but the company highlighted mitigating factors and positive open-label extension data. Separately, the Expanded Access Program for tumor hyperinsulinism showed strong positive results.

check_boxKey Events

• Phase 3 sunRIZE Study Misses Endpoints

  The pivotal Phase 3 sunRIZE study for ersodetug in congenital hyperinsulinism (HI) did not meet its primary or key secondary endpoints for reducing hypoglycemia events and time.

• Positive Data from Tumor HI Expanded Access Program

  Data from the Expanded Access Program (EAP) for tumor HI showed ersodetug led to a complete discontinuation of IV dextrose/TPN in 75% of the initial 9 participants.

• Continued Development for Congenital HI

  Despite the sunRIZE study results, Rezolute plans to engage with the FDA in Q1 2026 under Breakthrough Therapy Designation to discuss a path forward for ersodetug in congenital HI.

• Open-Label Extension Shows Promise

  All 59 participants who completed the sunRIZE study opted to continue in the open-label extension, with several children reportedly able to use ersodetug as monotherapy.

auto_awesomeAnalysis

Rezolute announced mixed clinical trial results for its lead candidate, ersodetug. The Phase 3 sunRIZE study for congenital hyperinsulinism (HI) failed to meet its primary and key secondary endpoints, which is a significant setback for this indication. However, the company emphasized evidence of pharmacologic activity, a notable placebo effect, and high retention rates in the open-label extension, where some patients achieved monotherapy. Concurrently, positive data from the Expanded Access Program for tumor HI demonstrated strong efficacy, with 75% of patients discontinuing IV dextrose/TPN, validating the drug's potential in this area and supporting the ongoing Phase 3 upLIFT study. The market is likely to react negatively to the primary endpoint miss in the congenital HI trial, but the strong tumor HI data and the company's continued pursuit of regulatory discussions for congenital HI may temper the overall impact. Investors should closely monitor the upcoming FDA discussions for congenital HI and the progress of the upLIFT study for tumor HI.